Cited by 4,262Protein Degradation and InhibitorsChromatin Remodeling and CancerEpigenetics and DNA Methylation

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Selective inhibition of BET bromodomains

Open access

Filippakopoulos, Panagis, Qi, Jun, Picaud, Sarah, Shen, Yao, Smith, William B., Fedorov, Oleg, Morse, Elizabeth M., Keates, Tracey, Hickman, Tyler T., Felletar, Ildiko, Philpott, Martin, Munro, Shonagh, McKeown, Michael R., Wang, Yuchuan, Christie, Amanda L., West, Nathan, Cameron, Michael J., Schwartz, Brian, Heightman, Tom D., La Thangue, Nicholas, French, Christopher A., Wiest, Olaf, Kung, Andrew L., Knapp, Stefan, Bradner, James E.·2010·Nature

DOI 10.1038/nature09504PMC PMC3010259

Open this paper in CoChat — free account

Abstract

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09504

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 273
Retracted
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,141
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 751

Flagged first, then by citations

Show all 42 references

2 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Sueoka, H., Komatsu, H., Kobayashi, H. & Ehara, S. Thienotriazolodiazepine Compounds and Medicinal Uses Thereof 1–50 (Yoshitomi Pharmaceutical Industries, Ltd, 1998)

Sorted by citations

Items 701–800 of 1,029

PROTAC degraders as chemical probes for studying target biology and target validation
Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98
Self-citation
Epigenome-Based Personalized Medicine in human Cancer
Yan, W., Herman, J. G., & Guo, M. (2015) · Epigenomics · doi:10.2217/epi.15.84 · Cited by 98
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia
Jin, Q., Martinez, C. A., Arcipowski, K. M., Zhu, Y., Gutierrez-Diaz, B. T., Wang, K. K., Johnson, M. R., Volk, A. G., Wang, F., Wu, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1740 · Cited by 98
BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
Sahai, V., Kumar, K., Knab, L. M., Chow, C. R., Raza, S. S., Bentrem, D. J., Ebine, K., & Munshi, H. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0925 · Cited by 98
The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
Zhao, Y., Yang, C., & Wang, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4014407 · Cited by 98
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
Odore, E., Lokiec, F. M., Cvitkovic, E., Békradda, M., Herait, P., Bourdel, F., Kahatt, C. M., Raffoux, E., Stathis, A., Thiéblemont, C., et al. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0327-6 · Cited by 97
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner
Mishra, V. K., Wegwitz, F., Kosinsky, R. L., Sen, M., Baumgartner, R., Wulff, T., Siveke, J. T., Schildhaus, H., Najafova, Z., Kari, V., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx212 · Cited by 97
Cellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 97
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
Watson, R. J., Bamborough, P., Barnett, H., Chung, C., Davis, R. P., Gordon, L. J., Grandi, P., Petretich, M., Phillipou, A., Prinjha, R. K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00614 · Cited by 97
Regulation of programmed cell death by Brd4
Hu, J., Pan, D., Guo, L., Chen, K., & Hu, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05505-1 · Cited by 100
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Vulpis, E., Borrelli, C., Zitti, B., Petrucci, M. T., Ricciardi, M. R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0362-2 · Cited by 97
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Winter, G. E., Rix, U., Carlson, S. M., Gleixner, K. V., Grebien, F., Gridling, M., Müller, A. C., Breitwieser, F. P., Bilban, M., Colinge, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1085 · Cited by 96
1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain
Demont, E. H., Bamborough, P., Chung, C., Craggs, P. D., Fallon, D. J., Gordon, L. J., Grandi, P., Hobbs, C. I., Hussain, J., Jones, E. J., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5002932 · Cited by 96
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
Kumar, K., Raza, S. S., Knab, L. M., Chow, C. R., Kwok, B., Bentrem, D. J., Popovic, R., Ebine, K., Licht, J. D., & Munshi, H. G. (2015) · Scientific Reports · doi:10.1038/srep09489 · Cited by 96
Enhancer and super-enhancer dynamics in repair after ischemic acute kidney injury
Wilflingseder, J., Willi, M., Lee, H., Olauson, H., Jankowski, J., Ichimura, T., Erben, R. G., Valerius, M. T., Hennighausen, L. G., & Bonventre, J. V. (2020) · Nature Communications · doi:10.1038/s41467-020-17205-5 · Cited by 96
BRD4 Prevents R-Loop Formation and Transcription-Replication Conflicts by Ensuring Efficient Transcription Elongation
Edwards, D. S., Maganti, R., Tanksley, J., Luo, J. D., Park, J. J. H., Balkanska-Sinclair, E., Ling, J., & Floyd, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108166 · Cited by 96
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 96
JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factorsPreprint
Chen, M., Zhu, N., Liu, X., Laurent, B., Tang, Z., Eng, R., Shi, Y., Armstrong, S. A., & Roeder, R. G. (2015) · Genes & Development · doi:10.1101/gad.267278.115 · Cited by 96
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas
Bouillez, A., Rajabi, H. N., Pitroda, S. P., Jin, C., Alam, M., Kharbanda, A., Tagde, A., Wong, K., & Kufe, D. W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1804 · Cited by 95
Family matters: How MYC family oncogenes impact small cell lung cancer
Brägelmann, J., Böhm, S., Guthrie, M. R., Mollaoglu, G., Oliver, T. G., & Sos, M. L. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1339849 · Cited by 95
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
Ameratunga, M., Braña, I., Bono, P., Postel-Vinay, S. C., Plummer, R., Aspegrén, J., Korjamo, T., Snapir, A., & Bono, J. S. D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01077-z · Cited by 95
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells
Lai, Y.-S., Chen, J.-Y., Tsai, H.-J., Chen, T. Y., & Hung, W. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.37 · Cited by 95
Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Lenhart, R., Kirov, S. A., Desilva, H., Cao, J., Lei, M., Johnston, K., Peterson, R., Schweizer, L., Purandare, A. V., Ross‐Macdonald, P., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0037 · Cited by 95
BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis
Hu, Y., Zhou, J., Ye, F., Xiong, H., Peng, L., Zheng, Z., Xu, F., Cui, M., Wei, C., Wang, X., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16011928 · Cited by 95
Targeting Hedgehog signaling pathway: Paving the road for cancer therapy
Salaritabar, A., Berindan‐Neagoe, I., Darvish, B., Hadjiakhoondi, F., Manayi, A., Devi, K. P., Barreca, D., Orhan, İ. E., Süntar, I. P., Farooqı, A. A., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.014 · Cited by 95
Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase–dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes
Xiao, Y., Liang, L., Huang, M., Qiu, Q., Zeng, S., Shi, M., Zou, Y., Ye, Y., Yang, X., & Xu, H. (2015) · Rheumatology · doi:10.1093/rheumatology/kev312 · Cited by 94
Discovery of a PCAF Bromodomain Chemical Probe
Moustakim, M., Clark, P. G. K., Trulli, L., de Arriba, A. L. F., Ehebauer, M. T., Chaikuad, A., Murphy, E. J., Méndez, J., Daniels, D. L., Hou, C.-F. D., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201610816 · Cited by 94
Self-citation
A chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 94
Self-citation
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 95
Perturbation of the c-Myc–Max Protein–Protein Interaction via Synthetic α-Helix Mimetics
Jung, K., Wang, H., Teriete, P., Yap, J. L., Chen, L., Lanning, M. E., Hu, A., Lambert, L. J., Holien, T., Sundan, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501440q · Cited by 94
Bromodomain Drug Discovery – the Past, the Present, and the Future
Pervaiz, M., Mishra, P., & Günther, S. (2018) · The Chemical Record · doi:10.1002/tcr.201800074 · Cited by 94
Discovery of an MLLT1/3 YEATS Domain Chemical Probe
Moustakim, M., Christott, T., Monteiro, O., Bennett, J. M., Giroud, C., Ward, J., Rogers, C. M., Smith, P., Panagakou, I., Saez, L. D., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201810617 · Cited by 93
Self-citation
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 93
The redox-senescence axis and its therapeutic targeting
Ngoi, N. Y. L., Liew, A. Q. X., Chong, S. J. F., Davids, M. S., Clement, M., & Pervaiz, S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102032 · Cited by 94
Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors
McKeown, M. R., Shaw, D. L., Fu, H., Liu, S., Xu, X., Marineau, J., Huang, Y., Zhang, X., Buckley, D. L., Kadam, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501120z · Cited by 93
Self-citation
BRD4 Phosphorylation Regulates HPV E2-Mediated Viral Transcription, Origin Replication, and Cellular MMP-9 Expression
Wu, S.-Y., Nin, D. S., Lee, A.-Y., Simanski, S., Kodadek, T. J., & Chiang, C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.001 · Cited by 93
ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia
Thirant, C., Ignacimouttou, C., Lopez, C. K., Diop, M. K., Mouël, L. L., Thiollier, C., Siret, A., Dessen, P., Aid, Z., Rivière, J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.006 · Cited by 93
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Bid, H. K., Phelps, D. A., Xaio, L., Guttridge, D. C., Lin, J., London, C. A., Baker, L. H., Mo, X. M., & Houghton, P. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0567 · Cited by 92
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 92
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Iniguez, A. B., Alexe, G., Wang, E. J., Roti, G., Patel, S., Chen, L., Kitara, S., Conway, A. S., Robichaud, A. L., Stolte, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.005 · Cited by 92
Self-citation
Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
Jia, Q., Chen, S., Tan, Y., Li, Y., & Tang, F. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0428-7 · Cited by 92
Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy
Zhou, M., Wang, J., Pan, J., Wang, H., Huang, L., Hou, B., Lai, Y., Wang, F., Guan, Q., Wang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39035-x · Cited by 92
Discovery of a Covalent Kinase Inhibitor from a DNA-Encoded Small-Molecule Library × Protein Library Selection
Chan, A. I., McGregor, L. M., Jain, T., & Liu, D. R. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04880 · Cited by 92
Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy
Moschini, M., Dell’Oglio, P., Lucianò, R., Gandaglia, G., Soria, F., Mattei, A., Klatte, T., Damiano, R., Shariat, S. F., Salonia, A., et al. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.12.006 · Cited by 91
Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons
Xiang, Y., Tanaka, Y., Patterson, B., Hwang, S., Hysolli, E., Çakır, B., Kim, K., Wang, W., Kang, Y., Clement, E. M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.016 · Cited by 93
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update
Mondal, P., Natesh, J., Penta, D., & Meeran, S. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.006 · Cited by 91
BRD4 orchestrates genome folding to promote neural crest differentiation
Linares-Saldana, R., Kim, W., Bolar, N. A., Zhang, H., Koch-Bojalad, B. A., Yoon, S., Shah, P. P., Karnay, A. M., Park, D. S., Luppino, J. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00934-8 · Cited by 91
Bromodomain Protein Brd4 Plays a Key Role in Merkel Cell Polyomavirus DNA Replication
Wang, X., Li, J., Schowalter, R. M., Jiao, J., Buck, C. B., & You, J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003021 · Cited by 91
Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells
Cribbs, A. P., Hookway, E. S., Wells, G., Lindow, M., Obad, S., Oerum, H., Prinjha, R. K., Athanasou, N. A., Sowman, A., Philpott, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000698 · Cited by 92
Self-citation
The impact of next-generation sequencing on the DNA methylation–based translational cancer research
Soto, J. A., Rodríguez‐Antolín, C., Vallespín, E., de Castro, J., & de Cáceres, I. I. (2015) · Translational research · doi:10.1016/j.trsl.2015.11.003 · Cited by 90
BET bromodomain proteins regulate enhancer function during adipogenesis
Brown, J. D., Feldman, Z. B., Doherty, S. P., Reyes, J. M., Rahl, P. B., Lin, C. Y., Sheng, Q., Duan, Q., Alexander Joel Federation, Kung, A. L., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711155115 · Cited by 90
Self-citation
Epigenetic Reader BRD4 (Bromodomain-Containing Protein 4) Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function
Kim, S. Y., Zhang, X., Schiattarella, G. G., Altamirano, F. J., Ramos, T. A. R., French, K. M., Jiang, N., Szweda, P. A., Evers, B. M., May, H. I., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047239 · Cited by 90
Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells
Qiu, Z., Zhao, L., Shen, J., Liang, Z., Wu, Q., Yang, K., Min, L., Gimple, R. C., Yang, Q., Bhargava, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1848 · Cited by 90
Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Tögel, L., Nightingale, R., Chüeh, A. C., Jayachandran, A., Tran, H., Phesse, T. J., Wu, R., Sieber, O. M., Arango, D., Dhillon, A. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0724 · Cited by 90
Self-citation
Advances in understanding the pathogenesis of graft‐versus‐host disease
Magenau, J. M., Runaas, L., & Reddy, P. R. (2016) · British Journal of Haematology · doi:10.1111/bjh.13959 · Cited by 90
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)
Bradbury, R. H., Callis, R. J., Carr, G. R., Chen, H., Clark, E. A., Feron, L. J. L., Glossop, S. C., Graham, M. A., Hattersley, M. M., Jones, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00070 · Cited by 90
Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
Hantschel, O. D. (2014) · ACS Chemical Biology · doi:10.1021/cb500886n · Cited by 87
Small-Molecule Targeting of BET Proteins in Cancer
French, C. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.04.001 · Cited by 89
Self-citation
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
Zhou, S., Treloar, A. E., & Lupien, M. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0745 · Cited by 89
JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer
Tian, Y., Wang, X., Zhao, S., Liao, X., Younis, M. R., Wang, S., Zhang, C., & Lu, G. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18730 · Cited by 89
Chromatin Hyperacetylation Impacts Chromosome Folding by Forming a Nuclear Subcompartment
Rosencrance, C. D., Ammouri, H., Yu, Q., Ge, T., Rendleman, E. J., Marshall, S. A., & Eagen, K. P. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.03.018 · Cited by 89
Proteolysis targeting chimeras (PROTACs) in cancer therapy
Ocaña, A., & Pandiella, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01672-1 · Cited by 89
The roles of epigenetics in cancer progression and metastasis
Chen, J. F.-Y., & Yan, Q. (2021) · Biochemical Journal · doi:10.1042/bcj20210084 · Cited by 89
The paradigm of drug resistance in cancer: an epigenetic perspective
Adhikari, S., Bhattacharya, A., Adhikary, S., Singh, V., Gadad, S. S., Roy, S., & Das, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211812 · Cited by 91
Multiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 92
Annotating MYC status with 89Zr-transferrin imaging
Holland, J. P., Evans, M. J., Rice, S. L., Wongvipat, J., Sawyers, C. L., & Lewis, J. S. (2012) · Nature Medicine · doi:10.1038/nm.2935 · Cited by 89
Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles
Fontaine, F. R., Overman, J. P., & François, M. (2015) · Cell Regeneration · doi:10.1186/s13619-015-0015-x · Cited by 89
Identification of a novel BET bromodomain inhibitor‐sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
Emadali, A., Rousseaux, S., Costa, J. B., Rome, C., Duley, S., Hamaidia, S., Betton-Fraisse, P., Debernardi, A., Leroux, D., Bernay, B., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202034 · Cited by 89
Bromodomains as therapeutic targets in cancer
Barbieri, I., Cannizzaro, E., & Dawson, M. A. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/elt007 · Cited by 88
NUT carcinoma in children and adults: A multicenter retrospective study
Lemelle, L., Pierron, G., Fréneaux, P., Huybrechts, S., Spiegel, A., Plantaz, D., Juliéron, M., Dumoucel, S., Italiano, A., Millot, F., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26693 · Cited by 88
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 88
Self-citation
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2020) · Pharmaceuticals · doi:10.3390/ph13050095 · Cited by 88
BET bromodomain inhibitors
Schwalm, M. P., & Knapp, S. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102148 · Cited by 89
Self-citation
Two faces of BRD4
Devaiah, B. N., & Singer, D. S. (2013) · Transcription · doi:10.4161/trns.22542 · Cited by 88
BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia
Costa, D. D., Agathanggelou, A., Perry, T., Weston, V., Petermann, E., Zlatanou, A., Oldreive, C., Wei, W., Stewart, G. S., Longman, J., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.24 · Cited by 88
Self-citation
Bioinformatics and variability in drug response: a protein structural perspective
Lahti, J. L., Tang, G. W., Capriotti, E., Liu, T., & Altman, R. B. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0843 · Cited by 89
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors
Daskalakis, M., Brocks, D., Sheng, Y.-H., Islam, S., Ressnerova, A., Assenov, Y., Milde, T., Oehme, I., Witt, O., Goyal, A., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442623 · Cited by 90
Epigenetic targets for novel therapies of lung diseases
Comer, B. S., Ba, M. A., Singer, C. A., & Gerthoffer, W. T. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.006 · Cited by 87
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes
Hill, J. M., Quenelle, D. C., Cardin, R. D., Vogel, J. L., Clément, C., Bravo, F., Foster, T. P., Bosch‐Marcé, M., Raja, P., Lee, J. S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010643 · Cited by 87
An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis
Matkar, S. S., Sharma, P., Gao, S.-B., Gurung, B., Katona, B. W., Liao, J., Muhammad, A. B., Kong, X.-C., Wang, L., Jin, G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.005 · Cited by 87
Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation
Xue, X., Zhang, Y., Liu, Z., Song, M., Xing, Y., Xiang, Q., Wang, Z., Tu, Z., Zhou, Y., Ding, K., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01511 · Cited by 87
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
Esteve‐Arenys, A., Valero, J. G., Chamorro-Jorganes, A., Gonzalez, D., Rodríguez, V., Dlouhy, I., Salaverría, I., Campo, E., Colomer, D., Martı́nez, A., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0111-1 · Cited by 87
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.04.028 · Cited by 89
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors
Bamborough, P., Chung, C., Furze, R. C., Grandi, P., Michon, A., Sheppard, R. J., Barnett, H., Diallo, H., Dixon, D. P., Douault, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00773 · Cited by 87
One-Pot Synthesis of 3,4,5-Trisubstituted 1,2,4-Triazoles via the Addition of Hydrazides to Activated Secondary Amides
Bechara, W. S., Хажиева, И. С., Rodrı́guez, E., & Charette, A. B. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b00128 · Cited by 87
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma
Sengupta, D., Kannan, A., Kern, M., Moreno, M. A., Vural, E. A., Stack, B. C., Suen, J. Y., Tackett, A. J., & Gao, L. (2015) · Epigenetics · doi:10.1080/15592294.2015.1034416 · Cited by 87
B Cells in Chronic Graft-versus-Host Disease
Sarantopoulos, S., Blazar, B. R., Cutler, C. S., & Ritz, J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.029 · Cited by 87
Fluorinated Aromatic Amino Acids Are Sensitive 19F NMR Probes for Bromodomain-Ligand Interactions
Mishra, N. K., Urick, A. K., Ember, S. W., Schönbrunn, E., & Pomerantz, W. C. K. (2014) · ACS Chemical Biology · doi:10.1021/cb5007344 · Cited by 87
Epigenetics in the hematologic malignancies
Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 87
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins
Raux, B., Voitovich, Y. V., Derviaux, C., Lugari, A., Rebuffet, E., Milhas, S., Priet, S., Roux, T., Trinquet, E., Guillemot, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01708 · Cited by 88
Self-citation
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 87
Biological function and histone recognition of family IV bromodomain‐containing proteins
Lloyd, J. T., & Glass, K. C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26010 · Cited by 88
ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer
Cai, L., Tsai, Y., Wang, P., Wang, J., Li, D., Fan, H., Zhao, Y., Bareja, R., Lu, R., Wilson, E. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.029 · Cited by 87
Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
Raeder, M. B., Birkeland, E., Trovik, J., Krakstad, C., Shehata, S., Schumacher, S. E., Zack, T. I., Krohn, A., Werner, H. M. J., Moody, S. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054873 · Cited by 86
BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo
Shao, Q., Kannan, A., Lin, Z., Stack, B. C., Suen, J. Y., & Gao, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0305 · Cited by 86
Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes
Dooley, K. E., Warburton, A., & McBride, A. A. (2016) · mBio · doi:10.1128/mbio.01446-16 · Cited by 86
The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumoursin vitroandin vivo
Jostes, S., Nettersheim, D., Fellermeyer, M., Schneider, S., Hafezi, F., Honecker, F. U., Schumacher, V., Geyer, M., Kristiansen, G., & Schorle, H. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13059 · Cited by 86
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
Zhang, X., Lee, H. C., Shirazi, F., Baladandayuthapani, V., Lin, H. Y., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Singh, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0044-x · Cited by 86
Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Morrison-Smith, C. D., Knox, T. M., Filic, I., Soroko, K. M., Eschle, B. K., Wilkens, M. K., Gokhale, P. C., Giles, F. J., Griffin, A. M., Brown, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0087 · Cited by 86
Self-citation

Authors: Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., & Bradner, J. E.
Affiliations: University of Oxford (GB)
Harvard University (US)
University of Notre Dame (US)
Brigham and Women's Hospital (US)
Boston Children's Hospital (US)
Corresponding author: Knapp, Stefan
Bradner, James E.
ORCID: Filippakopoulos, Panagis
Qi, Jun
Picaud, Sarah
Shen, Yao
Fedorov, Oleg
Hickman, Tyler T.
Philpott, Martin
Munro, Shonagh
McKeown, Michael R.
Wang, Yuchuan
Schwartz, Brian
Heightman, Tom D.
French, Christopher A.
Wiest, Olaf
Kung, Andrew L.
Knapp, Stefan
Bradner, James E.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-09-24
Volume: 468
Issue: 7327
Pages: 1067-1073
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09504
PMC: PMC3010259
OpenAlex: W2041535798
Cited by: 4,262
References: 42
Citations by year: 2026: 217 · 2025: 307 · 2024: 304 · 2023: 307 · 2022: 309 · 2021: 323 · 2020: 340 · 2019: 323 · 2018: 303 · 2017: 306 · 2016: 334 · 2015: 279 · 2014: 246 · 2013: 177 · 2012: 117
FWCI: 48.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
Funders: Wellcome Trust
Cancer Research UK (13058)
U.S. Public Health Service (T32-075762)
Canadian Institutes of Health Research
National Cancer Institute (K08CA128972)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: BET inhibitors, JQ1, BRD4, epigenetic reader protein, protein-protein interaction inhibition, squamous cell carcinoma, histone acetylation, co-crystal structure, chemical probes, transcriptional regulation
MeSH terms: Bromodomain Containing Proteins, Amino Acid Sequence, Animals, Azirines, Binding Sites, Carcinoma, Squamous Cell, Cell Differentiation, Chromatin, Dihydropyridines, Female, Humans, Mice, Nude, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Protein Binding, Recombinant Proteins, Skin Neoplasms, Stereoisomerism, Transcription Factors, Sequence Alignment, Protein Structure, Tertiary, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective inhibition of BET bromodomains

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks